REG - Byotrol PLC - PDMR Shareholding

ByotrolAnnouncement

27/09/2022 11:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220927:nRSa8562Aa&default-theme=true

RNS Number : 8562A  Byotrol PLC  27 September 2022

 

Byotrol plc

("Byotrol" or the "Company")

 

PDMR Dealing

 

Byotrol plc (AIM: BYOT), the developer of anti-microbial hygiene technologies,
announces that on 27 January 2022, Vivan Pinto, a PDMR of the Company,
purchased 100,000 ordinary shares of 0.25p each ("Ordinary Shares") at an
average price of 5.24p per Ordinary Share (the "Purchase"). Due to an
administrative oversight the Purchase was not announced at the date of
transaction.

 

Following the Purchase, Vivan Pinto has an interest in 300,000 Ordinary Shares
representing 0.07% of the total voting rights of the Company. As announced on
28 July 2022, Vivan Pinto subscribed for convertible loan notes in the
Company, which if converted would represent an additional 0.70% of the total
voting rights of the Company.

 

 

 Byotrol Plc
 David Traynor - Chief Executive Officer                               +44 (0)1925 742 000
 Chris Sedwell - Chief Financial Officer

 finnCap Limited (Nominated Adviser and Broker)                        +44 (0)20 7220 0500
 Geoff Nash / James Thompson - Corporate Finance
 Richard Chambers - ECM

 Flagstaff Strategic and Investor Communications                       +44 (0)20 7129 1474
 Tim Thompson/Andrea Seymour/Fergus Mellon                             byotrol@flagstaffcomms.com (mailto:byotrol@flagstaffcomms.com)

 

The information communicated in this announcement contains inside information
for the purposes of Article 7 of the Market Abuse Regulation (EU) No.
596/2014.

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a leading infection prevention and
control company, operating globally in the animal health, human health,
facilities management, and consumer sectors.

 

Byotrol develops unique antimicrobial technologies for use on surfaces, skin
and instruments, which it then commercialises through market-leading
distribution partners in each sector.

 

Byotrol's antimicrobial technologies can be licensed for use in leading
brands, to significantly improve their product claims, while reassuring
consumers and end-users of their efficacy and quality.

 

Founded in 2005, the Company develops technologies and products with the aim
of providing easier, safer and cleaner lives for everyone.

 

 

 

 1.    Details of the person discharging managerial responsibilities/person closely
       associated
 a)    Name:                                                         Vivan Pinto
 2.    Reason for the notification
 a)    Position/status:                                              PDMR
 b)    Initial notification/Amendment:                               Initial Notification
 3.    Details of the issuer, emission allowance market participant, auction
       platform, auctioneer or auction monitor
 a)    Name:                                                         Byotrol plc
 b)    LEI:                                                          213800AJMTSTIPA59A34
 4.    Details of the transaction(s): section to be repeated for (i) each type of
       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
       place where transactions have been conducted
 a)    Description of the financial instrument, type of instrument:  Ordinary shares of 0.25 pence per share

       Identification code:                                          GB00B0999995
 b)    Nature of the transaction:                                    Purchase of Ordinary Shares

 c)    Price(s) and volume(s):                                       Price(s)  Volume(s)
                                                                     5.24p     100,000

 d)    Aggregated information:

       ·Aggregated volume:                                           100,000 Ordinary Shares

       ·Price:                                                       £5,240

 e)    Date of the transaction:                                      27 January 2022
 f)    Place of the transaction:                                     AIM, London Stock Exchange (XLON)

d)

Aggregated information:

·Aggregated volume:

·Price:

 

 

100,000 Ordinary Shares

£5,240

 

e)

Date of the transaction:

27 January 2022

f)

Place of the transaction:

AIM, London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHPPUCGBUPPGUM